Neu oO e’s FDA 510(k)-Clea ed O eRF T igemi al Ne ve Ablatio System Offe s Hope fo Patie ts Suffe i g f om T igemi al Neu algia
EDEN PRAIRIE, Mi ., Oct. 27, 2026 (GLOBE NEWSWIRE) — Neu oO e Medical Tech ologies Co po atio (Nasdaq: NMTC) (“Neu oO e” o the “Compa y”), a medical tech ology compa y dedicated to t a sfo mi g the su gical diag osis a d t eatme t of eu ological diso de s, today highlighted a featu e a ticle published i the New Yo k Post showcasi g the successful t eatme t of a patie t* suffe i g f om t igemi al eu algia, a debilitati g eu ological co ditio , usi g the Compa y’s FDA 510(k)-clea ed O eRF® T igemi al Ne ve Ablatio System.
The New Yo k Post a ticle ch o icles the ema kable jou ey of Natisha “Tish” Lo g, a mothe of fou who e du ed seve yea s of exc uciati g facial pai that seve ely impacted he ability to sleep, wo k, smile, a d pe fo m eve yday activities. Afte medicatio s a d a p evious i vasive b ai su ge y failed to p ovide lasti g elief, Ms. Lo g became the fi st patie t i the wo ld to u de go t igemi al e ve ablatio usi g Neu oO e’s O eRF System at U ive sity Hospitals i Clevela d, Ohio.
Followi g the mi imally i vasive p ocedu e, which ca be as sho t as 20 to 30 mi utes, Ms. Lo g expe ie ced immediate elief f om the debilitati g pai that had domi ated he life fo yea s a d emai ed pai -f ee at the time of the a ticle’s publicatio . The a ticle also featu es comme ta y f om eu osu geo D . Michael Staudt of U ive sity Hospitals, who pe fo med the p ocedu e a d highlighted the adva tages of Neu oO e’s tech ology.
U like co ve tio al adiof eque cy ablatio p obes that equi e epeated epositio i g to ide tify a d t eat diffe e t e ve locatio s, Neu oO e’s O eRF T igemi al Ne ve Ablatio System e ables physicia s to test multiple e ve locatio s th ough a si gle p obe i se tio , offe i g patie ts a mo e comfo table p ocedu e compa ed to k ow comme cially available t igemi al e ve adiof eque cy (RF) ablatio systems.
“This is o e of ma y patie t success sto ies we have see with O eRF fo t igemi al eu algia, a d it is i c edibly ewa di g to see the p ofou d impact ou tech ology ca have o patie ts suffe i g f om this devastati g co ditio ,” said Dave Rosa, Chief Executive Office of Neu oO e. “Sto ies like this ei fo ce ou se se of u ge cy a d espo sibility to make this tech ology available to mo e patie ts. We a e actively expa di g ou di ect sales a d dist ibutio effo ts to accele ate comme cializatio a d b oade access to ou O eRF T igemi al Ne ve Ablatio System ac oss the cou t y.”
Neu oO e Medical Tech ologies Co po atio is a medical tech ology compa y focused o imp ovi g su gical ca e optio s a d outcomes fo patie ts suffe i g f om eu ological diso de s. Neu oO e ma kets a mi imally i vasive a d high-defi itio /high-p ecisio elect ode tech ology platfo m with fou FDA-clea ed p oduct families: Evo® Co tical Elect odes, Evo® sEEG Elect odes, O eRF® Ablatio System (fo b ai ), a d O eRF® T igemi al Ne ve Ablatio System.
This p ess elease may i clude fo wa d-looki g stateme ts withi the mea i g of Sectio 27A of the Secu ities Act of 1933, as ame ded, a d Sectio 21E of the Secu ities Excha ge Act of 1934, as ame ded. Except fo stateme ts of histo ical fact, a y i fo matio co tai ed i this p ess elease may be a fo wa d–looki g stateme t that eflects Neu oO e’s cu e t views about futu e eve ts a d a e subject to k ow a d u k ow isks, u ce tai ties a d othe facto s that may cause ou actual esults, levels of activity, pe fo ma ce o achieveme ts to be mate ially diffe e t f om the i fo matio exp essed o implied by these fo wa d-looki g stateme ts. I some cases, you ca ide tify fo wa d–looki g stateme ts by the wo ds o ph ases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “i te d,” “pla ,” “objective,” “a ticipate,” “believe,” “estimate,” “p edict,” “p oject,” “pote tial,” “ta get,” “seek,” “co template,” “co ti ue, “focused o ,” “committed to” a d “o goi g,” o the egative of these te ms, o othe compa able te mi ology i te ded to ide tify stateme ts about the futu e. Fo wa d–looki g stateme ts may i clude stateme ts ega di g the expa sio of Neu oO e’s di ect sales a d dist ibutio effo ts to accele ate comme cializatio a d b oade access to the O eRF T igemi al Ne ve Ablatio System. Although Neu oO e believes that we have a easo able basis fo each fo wa d-looki g stateme t, we cautio you that these stateme ts a e based o a combi atio of facts a d facto s cu e tly k ow by us a d ou expectatio s of the futu e, about which we ca ot be ce tai . Ou actual futu e esults may be mate ially diffe e t f om what we expect due to facto s la gely outside ou co t ol, i cludi g isks that ou pa t e ships may ot facilitate the comme cializatio o ma ket accepta ce of ou tech ology; whethe due to supply chai dis uptio s, labo sho tages, isks that ou tech ology will ot pe fo m as expected based o esults of ou p e-cli ical a d cli ical t ials; isks elated to u ce tai ties associated with the Compa y’s capital equi eme ts to achieve its busi ess objectives a d ability to aise additio al fu ds: the isk that we may ot be able to secu e o etai cove age o adequate eimbu seme t fo ou tech ology; u ce tai ties i he e t i the developme t p ocess of ou tech ology; isks elated to cha ges i egulato y equi eme ts o decisio s of egulato y autho ities; that we may ot have accu ately estimated the size a d g owth pote tial of the ma kets fo ou tech ology; isks elated to ou ability to p otect ou i tellectual p ope ty ights; a d othe isks, u ce tai ties a d assumptio s, i cludi g those desc ibed u de the headi g “Risk Facto s” i ou fili gs with the Secu ities a d Excha ge Commissio . These fo wa d–looki g stateme ts speak o ly as of the date of this p ess elease a d Neu oO e u de takes o obligatio to evise o update a y fo wa d–looki g stateme ts fo a y easo , eve if ew i fo matio becomes available i the futu e.
Cautio : Fede al law est icts this device to sale by o o the o de of a physicia .
*Disclaime : This ecou ts a specific patie ts’ expe ie ces a d may ot be ep ese tative of all patie t outcomes.
